阿比特龙联合泼尼松治疗去势抗拒前列腺癌的临床观察
DOI: 10.3971/j.issn.1000-8578.2015.04.014
Keywords: 醋酸阿比特龙,泼尼松,去势抗拒前列腺癌,疗效,安全性,Comparison of Long-term Efficacy of IMRT plus Concurrent Chemotherapy Versus Neoadjuvant Chemotherapy Followed by IMRT plus Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma,Efficacy and Safety of Weekly Liposome-paclitaxel or Oxaliplatin Combined with Tegafur on Elderly Advanced Gastric Cancer,Relationship Between Lymphocyte Nadir and Radiotherapy Efficacy or Prognosis of Patients with Esophageal Carcinoma,Therapeutic Effect of Interferon on Chronic Myeloproliferative Neoplasm Patients,Feasibility of Simultaneous Integrated Boost Conformal Radiotherapy on Nonresectable Central Non-small Cell Lung Cancer,Changes of Beclin-1 mRNA Expression for Predicting Efficacy of Introperitoneal Cisplatin in Treatment of Gastric Cancer with Malignant Ascites,Oxaliplatin Combined with S-1 plus Bevacizumab Regimen in Treatment of Advanced Colorectal Cancer,Significance of TYMS and ERCC1 Gene Polymorphism in Peripheral Venous Blood in Evaluating the Chemotherapeutic Effect on Patients with Gastroenteric Tumor Patients,Clinical Efficacy of Neoadjuvant Chemotherapy with FOLFOX4 Regimen in Advanced Gastric Carcinoma,Microwave Ablation Combined with Stereotactic Radiotherapy for Primary and Recurrent Hepatocellular Carcinoma after Interventional Treatment,Correlation between BCRP Expression and Efficacy of Neoadjuvant Chemotherapy,Effects of Stability Plasma Concentration of 5-Fu and Docetaxel on Adverse Events and#br# Short Term Effect after 5-Fu and Docetaxel Chemotherapy,Application of Allogeneic Stem Cell Transplantation in Younger Patients with Multiple Myeloma,Experimental Study of Efficacy of Multi-target Inhibitor Combined with Cytotoxic Treatment on Malignant Glioma,Clinical Study of Bevacizumab Combined with FOLFIRI Regimen in Treatment of Advanced Colorectal Cancer
Abstract:
摘要 目的 探讨新型雄激素合成抑制剂醋酸阿比特龙（Abriaterone acetate）治疗去势抗拒前列腺癌（castration-resistant prostate cancer，CRPC）的疗效及安全性。方法 经病理证实并符合入选标准的58例去势抗拒前列腺癌患者，中位年龄68岁（61~81岁），接受醋酸阿比特龙治疗，化疗至少2周期后。按实体瘤疗效评价标准（RECIST）美国NCI制定的毒性评价指标（CTC-AE3.0）评价疗效和毒性反应；采用Kaplan-meier法对患者总生存时间（OS）进行分析。结果 5例未完成总评估过程。可评价疗效的53例患者中，总有效率（ORR）18.87%（10例），疾病控制率（DCR）62.26%（33例）；中位OS为（15.0±1.2）月； 28例前列腺特异性抗原（prostate-specific antigen，PSA）下降﹥50%，治疗前后PSA中位数分别为78 ng/ml（18~1 776 ng/ml）和37 ng/ml（9~320 ng/ml），两者比较差异有统计学意义（P﹤0.05） ；化疗不良反应多为Ⅰ~Ⅱ级。结论 阿比特龙联合泼尼松治疗去势抗拒前列腺癌疗效较好，不良反应轻
Full-Text
